Taking ICIs as an example, PD-L1 expression, tumor-infiltrating lymphocytes, tumor mutation burden (TMB) and mismatch repair deficiency status were all able to affect the efficacy of ICIs [39, 40]. Here, CD274 is linked to neoplasm.